By: ChinaBio® Today
June 01, 2013 at 06:13 AM EDT
Week in Review: BeiGene Sells Novel Cancer Drug to Merck Serono
BeiGene of Beijing out-licensed the ex-China rights for a novel, near-clinical-stage cancer drug to Merck Serono; Valeant Pharma bought Bausch & Lomb for $8.7 billion, acquiring an eye care product portfolio and a sales foothold in China; Tongjitang Chinese Medicines will be bought by Winteam Pharma for $393 million, almost three times its take-private price; Qiagen announced a biomarker-diagnostics R&D JV with Suzhou’s BioBay Life Science Park; Aslan Pharma of Singapore reported positive results from a Phase II trial of ASLAN001 in gastric cancer patients; Sinovac said its filing for approval of an EV71 vaccine was accepted by the Beijing Drug Administration; Beijing Vigoo Biological announced its enterovirus 71 vaccine was effective in up to 90% of test subjects; and, in 2012, pharmaceutical sales in China topped the one trillion RMB level for the first time, hitting 1.12 trillion RMB ($181.2 billion). More details…. Stock Symbols: (NYSE: VRX) (HK: 570) (NSDQ: QGEN) (NSDQ: SVA) Share this with colleagues: // //
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here